Exactus, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXDI research report →
Companywww.exactushemp.com
Exactus, Inc. produces and supplies hemp-derived ingredients and feminized hemp genetics. It provides cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products to the cosmetic, wellness, food, beverage, pharmaceutical, and pet industries.
- CEO
- Alvaro Daniel Alberttis
- IPO
- 2015
- HQ
- Delray Beach, FL, US
Valuation
- Market Cap
- $0
- P/E
- -0.30
- P/S
- 0.00
- P/B
- -1.07
- EV/EBITDA
- -0.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -100.00%
- Op Margin
- -388.05%
- Net Margin
- -402.24%
- ROE
- -1825.27%
- ROIC
- 289.78%
Growth & Income
- Revenue
- $2.72M · 686.85%
- Net Income
- $-10,941,000 · -12.95%
- EPS
- $-0.22 · 24.14%
- Op Income
- $-10,555,000
- FCF YoY
- 88.99%
Performance & Tape
- 52W High
- $3.33
- 52W Low
- $0.04
- 50D MA
- $1.42
- 200D MA
- $0.43
- Beta
- 4.32
- Avg Volume
- 15.90K
Get TickerSpark's AI analysis on EXDI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 22, 21 | Wert Lawrence | other | 3,500,000 |
| Jan 22, 21 | Alberttis Alvaro Daniel | other | 2,039,241 |
| Jan 22, 21 | Alberttis Alvaro Daniel | other | 2,500,000 |
| Jan 22, 21 | Johnson Andrew L. | other | 8,186,240 |
| Jan 22, 21 | Johnson Andrew L. | other | 3,500,000 |
| Feb 1, 20 | Puzder Ken | other | 250,000 |
| Jan 16, 20 | Alberttis Alvaro Daniel | other | 0 |
| Dec 18, 19 | Johnson Andrew L. | buy | 62,500 |
| Dec 11, 19 | Ceed2Med LLC | other | 1,200,000 |
| Nov 20, 19 | ESVAL KEVIN JAMES | other | 100,000 |
Our EXDI Coverage
We haven't published any research on EXDI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EXDI Report →